2026
Biotech investor readiness: evidence, milestones and narrative before the pitch deck
Why early-stage life-sciences companies need evidence discipline, commercial logic and a clear strategic narrative before investor outreach.
Read insightInsights
Perspectives on life-sciences strategy, evidence quality and investor readiness.
Short strategic notes for founders, investors and leadership teams working at the intersection of science, healthcare innovation and commercial execution.
2026
Turning complex science into an investor-ready narrative
How scientific complexity can be translated into a clear external story without oversimplifying the biology or weakening credibility.
Read insight2026
What diagnostics companies should prepare before strategic outreach
A practical view of evidence, positioning and buyer logic for diagnostics and AI-enabled healthcare platforms.
Read insightNext step
Use the insights as a starting point for a scientific-commercial review.
For investor-readiness reviews, business development support or scientific-commercial positioning, start with a confidential conversation.